ClinicalTrials.gg
TerminatedNCT04140695Updated May 14, 2024Results posted

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)

A Phase 3 interventional study of Tradipitant and Placebo in Atopic Dermatitis, sponsored by Vanda Pharmaceuticals. Terminated at 51 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-05-14.

Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment

Why this study was terminated
Business Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
281st of 544
87 · median 96
Started
2019
with 57 others
Phase 3
103 of 639
8 open now
Registered
348th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 281st largest by enrollment of the 544 interventional ones that give a count, is one of 58 that started in 2019, is one of 103 in phase 3, and was the 348th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Chronic Pruritus
  • Eczema
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and non-pregnant, non-lactating female patients aged 18 - 70 years (inclusive);
  • Diagnosed with atopic dermatitis;
  • Suffering from chronic pruritus;
  • (BMI) of ≥18 and ≤40 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Chronic pruritus due to condition other than atopic dermatitis (AD);
  • A positive test for drugs of abuse at the screening or evaluation visits;
  • Exposure to any medication in the past 60 days
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Tradipitant

    Oral Capsule

    Drug: Tradipitant

  • Placebo comparator
    Placebo

    Oral Capsule

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Worst Itch Numeric Rating Scale (WI-NRS) Responder Rate at Week 2

    The WI-NRS responder is defined as a patient achieving at least 4 points reduction from baseline in weekly average of diary WI-NRS. Responses were measured on a scale of 0 - 10, with 0 being "no itch" and 10 being the "worst itch imaginable".

    Time frame: 2 weeks

07

Results

Posted May 14, 2024
Limitations and caveats
This study was discontinued early and therefore the study was not powered for appropriate examination of primary and secondary endpoints.

Participant flow

Participant flow — Overall Study
MilestoneTradipitantPlacebo
Started4344
Completed3332
Not completed1012

Outcome measures

PrimaryWorst Itch Numeric Rating Scale (WI-NRS) Responder Rate at Week 2

The WI-NRS responder is defined as a patient achieving at least 4 points reduction from baseline in weekly average of diary WI-NRS. Responses were measured on a scale of 0 - 10, with 0 being "no itch" and 10 being the "worst itch imaginable".

Time frame:
2 weeks
Reported as:
Count of participants · Participants
Worst Itch Numeric Rating Scale (WI-NRS) Responder Rate at Week 2
ParticipantsTradipitantPlacebo
Worst Itch Numeric Rating Scale (WI-NRS) Responder Rate at Week 224

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent through study completion (approximately 14 weeks) regardless of seriousness or relationship to investigational product. Patients with non-serious AEs that are ongoing at the patient's last study visit must be followed until resolution or for 30 days after the patient's last study visit, whichever comes first.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tradipitant0/43 (0%)1/43 (2.3%)13/43 (30.2%)
Placebo0/44 (0%)1/44 (2.3%)10/44 (22.7%)
Most frequent serious events
Most frequent serious events
EventTradipitantPlacebo
Procedural ComplicationInjury, poisoning and procedural complications1/430/44
Obstructive PancreatitisGastrointestinal disorders0/431/44
Most frequent other events
Showing 10 of 32
Most frequent other events
EventTradipitantPlacebo
Upper Respiratory Tract InfectionInfections and infestations2/431/44
Dry MouthGastrointestinal disorders2/430/44
ParesthesiaNervous system disorders2/430/44
SomnolenceNervous system disorders2/430/44
DiarrheaGastrointestinal disorders1/432/44
NauseaGastrointestinal disorders0/432/44
Dermatitis AtopicSkin and subcutaneous tissue disorders0/432/44
ConjunctivitisInfections and infestations1/430/44
Herpes Virus InfectionInfections and infestations1/430/44
Skin InfectionInfections and infestations1/430/44

Baseline characteristics

Age, Continuous
Age, Continuous(years)TradipitantPlaceboTotal
Mean41.7 ± 14.6339.2 ± 15.1040.4 ± 14.84
Sex: Female, Male
Sex: Female, Male(Participants)TradipitantPlaceboTotal
Female252651
Male181836
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TradipitantPlaceboTotal
Hispanic or Latino121527
Not Hispanic or Latino302858
Unknown or Not Reported112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TradipitantPlaceboTotal
American Indian or Alaska Native235
Asian538
Black or African American121022
Native Hawaiian or Other Pacific Islander101
White222850
Other101
Region of Enrollment
Region of Enrollment(Participants)TradipitantPlaceboTotal
United States434487
08

Study locations

51 sites
  • Vanda Investigational Site
    Hoover, Alabama 35244, United States
  • Vanda Investigational Site
    Tempe, Arizona 85281, United States
  • Vanda Investigational Site
    Encino, California 91436, United States
  • Vanda Investigational Site
    Fountain Valley, California 92708, United States
  • Vanda Investigational Site
    Laguna Hills, California 92653, United States
  • Vanda Investigational Site
    Lomita, California 90717, United States
  • Vanda Investigational Site
    Los Angeles, California 90025, United States
  • Vanda Investigational Site
    Los Angeles, California 90036, United States
  • Vanda Investigational Site
    Los Angeles, California 90057, United States
  • Vanda Investigational Site
    Denver, Colorado 80220, United States
  • Vanda Investigational Site
    Clearwater, Florida 33756, United States
  • Vanda Investigational Site
    Miami, Florida 33126, United States
  • Vanda Investigational Site
    Tampa, Florida 33613, United States
  • Vanda Investigational Site
    Savannah, Georgia 31406, United States
  • Vanda Investigational Site
    Boise, Idaho 83704, United States
  • Vanda Investigational Site
    Chicago, Illinois 60611, United States
  • Vanda Investigational Site
    Normal, Illinois 61761, United States
  • Vanda Investigational Site
    Skokie, Illinois 60077, United States
  • Vanda Investigational Site
    Plainfield, Indiana 46168, United States
  • Vanda Investigational Site
    Crowley, Louisiana 70526, United States
  • Vanda Investigational Site
    Timonium, Maryland 21093, United States
  • Vanda Investigational Site
    Fort Gratiot, Michigan 48059, United States
  • Vanda Investigational Site
    Saint Joseph, Missouri 64506, United States
  • Vanda Investigational Site
    Saint Louis, Missouri 63141, United States
  • Vanda Investigational Site
    Omaha, Nebraska 68144, United States
  • Vanda Investigational Site
    Las Vegas, Nevada 89119, United States
  • Vanda Investigational Site
    Berlin, New Jersey 08009, United States
  • Vanda Investigational Site
    Hoboken, New Jersey 07030, United States
  • Vanda Investigational Site
    Verona, New Jersey 07044, United States
  • Vanda Investigational Site
    Bronx, New York 10458, United States
  • Vanda Investigational Site
    Kew Gardens, New York 11415, United States
  • Vanda Investigational Site
    New York, New York 10022, United States
  • Vanda Investigational Site
    New York, New York 10075, United States
  • Vanda Investigational Site
    Charlotte, North Carolina 28277, United States
  • Vanda Investigational Site
    Cincinnati, Ohio 45212, United States
  • Vanda Investigational Site
    Oklahoma City, Oklahoma 73112, United States
  • Vanda Investigational Site
    Tulsa, Oklahoma 74136, United States
  • Vanda Investigational Site
    Philadelphia, Pennsylvania 19103, United States
  • Vanda Investigational Site
    Johnston, Rhode Island 02919, United States
  • Vanda Investigational Site
    Spartanburg, South Carolina 29301, United States
  • Vanda Investigational Site
    Spartanburg, South Carolina 29303, United States
  • Vanda Investigational Site
    Dallas, Texas 75230, United States
  • Vanda Investigational Site
    Houston, Texas 77004, United States
  • Vanda Investigational Site
    Houston, Texas 77065, United States
  • Vanda Investigational Site
    Mesquite, Texas 75149, United States
  • Vanda Investigational Site
    South Jordan, Utah 84095, United States
  • Vanda Investigational Site
    South Burlington, Vermont 05403, United States
  • Vanda Investigational Site
    Alexandria, Virginia 22311, United States
  • Vanda Investigational Site
    Newport News, Virginia 23606, United States
  • Vanda Investigational Site
    Norfolk, Virginia 23502, United States
  • Vanda Investigational Site
    Spokane, Washington 99202, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Oct 2020, 11 months.

Results were first posted in May 2024, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2019
First posted
Oct 28, 2019
StartActual
Oct 21, 2019
Primary completionActual
Oct 14, 2020
CompletionActual
Oct 14, 2020
Results first posted
May 14, 2024
Last update
May 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04140695
Responsible party
Sponsor
First posted
Oct 28, 2019
Start date
Oct 21, 2019
Primary completion
Oct 14, 2020
Completion
Oct 14, 2020
Results posted
May 14, 2024
Last update
May 14, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tradipitant

Start the discussion